SCP Vitalife

SCP Vitalife seeks to invest in early- to mid-stage stage life science companies with exceptional technology or other proprietary advantages that are poised to capitalize on major market trends. Over half of the Fund's investment capital is expected to go to Israeli companies with the remainder allocated to U.S. companies. Our target initial investment size is $3 - $7 million, with typical total investment of $7-$15 million over the lifespan of the investment.

Investment Areas

The Fund's major focus for investment will be:
• Medical devices for therapeutic uses;
• Novel diagnostic methods, especially imaging;
• Biomaterials;
• Specialty pharmaceuticals and drug delivery; and
• Healthcare services.

Geographic Focus

SCP Vitalife believes that Israel presents an excellent source of life science technology investment opportunities, particularly in the area of medical devices. The Israeli life science industry has experienced consistent growth during the past decade, with the establishment of approximately 50 to 60 companies per year since 2000. Additionally, Israel's total number of granted patents in the medical device area positions it in first place worldwide in patents per capita and number seven in absolute number of patents . SCP Vitalife will be able to draw upon its strong relationships with Israel's globally renowned academic institutions and its unique network of relationships with key technology sources in the Israel defense industry .